Assessment of Baseline Plasma p‐tau217 in TANGO, a Randomized, Placebo‐controlled Phase 2 Study of Gosuranemab in Patients with Early Alzheimer’s Disease

Julie Czerkowicz, Rui Zhang, Jessica Collins, Carrie E. Rubel, John O’Gorman, Melanie Shulman, Danielle GrahamAlzheimer 2024 · DOI

TL;DR

This study explored the utility of plasma p-tau217 as a biomarker for Alzheimer's Disease (AD) in the TANGO clinical trial. They found that baseline p-tau217 levels strongly correlate with amyloid and tau PET imaging, key AD pathologies, and predict faster clinical decline, suggesting its potential as a prognostic biomarker for AD.

What Problem Does This Paper Address?

Diagnosing Alzheimer's Disease (AD) and accurately predicting its progression can be challenging. While PET imaging can visualize AD's hallmark pathologies (amyloid plaques and tau tangles), it's invasive and expensive. The search for reliable, accessible blood-based biomarkers that can reflect these pathologies and predict disease trajectory is crucial for improving diagnosis, patient selection for clinical trials, and monitoring disease progression. This paper investigates whether plasma p-tau217, a specific form of phosphorylated tau protein, can serve as such a biomarker in the context of a clinical trial for a novel AD treatment.

Methods

The researchers analyzed plasma samples collected from participants in the TANGO Phase 2 study, which investigated the efficacy of gosuranemab, an anti-tau antibody. They measured plasma levels of p-tau217 using the ALZpath Quanterix Simoa assay and p-tau181 using a similar assay. To validate these findings against established AD pathology markers, they also utilized data from amyloid PET and tau PET imaging performed on a subset of participants. Clinical decline was assessed using standard cognitive scales like the CDR-SB, MMSE, ADAS-Cog13, and ADCS-ADL. Statistical analysis primarily involved Spearman correlation to assess the relationships between these different measures.

Datasets

The study utilized data from the TANGO Phase 2 clinical trial.

  • Participants: 554 randomized participants in the TANGO trial.
  • Plasma Samples: Collected at baseline and up to Week 78.
  • Imaging Data:
    • Amyloid PET (18F-florbetapir) from 322 participants at screening.
  • Tau PET (18F-MK-6240) from 357 participants at baseline and Weeks 52 and 78.
  • Clinical Data: Cognitive assessments (CDR-SB, MMSE, ADAS-Cog13, ADCS-ADL) collected at various time points.

This dataset is specific to the TANGO trial and is not a newly introduced public benchmark.

Key Insights and Ideas

  • Plasma p-tau217 as a proxy for AD pathology: The strong correlations between plasma p-tau217 and both amyloid and tau PET imaging suggest that this blood biomarker can effectively reflect the underlying neuropathological hallmarks of AD. This is a significant finding as it offers a less invasive way to infer these pathologies.
  • Prognostic potential: The observation that higher baseline p-tau217 levels are associated with a greater rate of clinical decline highlights its potential as a prognostic marker. This means it could help predict how quickly a patient's cognitive function might worsen.
  • Complementary to p-tau181: The study confirmed a strong correlation between p-tau217 and another established AD blood biomarker, p-tau181, suggesting they might offer complementary information or reinforce each other's findings.

Key Results

  • Correlation with other biomarkers: Baseline plasma p-tau217 was highly correlated with baseline plasma p-tau181 (Spearman = 0.7617, p < 0.0001).
  • Correlation with PET imaging:
    • Baseline p-tau217 correlated with baseline amyloid PET (Spearman = 0.4294, p < 0.0001).
  • Baseline p-tau217 correlated with baseline tau PET across different Braak stages (Spearman range = 0.4075-0.6163, p < 0.0001).
  • Prediction of clinical decline: Participants with higher baseline plasma p-tau217 showed a greater rate of clinical decline by Week 78.

Limitations and Future Work

  • Exploratory Analysis: The authors acknowledge that this was an exploratory analysis within the TANGO trial.
  • Need for further validation: They emphasize that additional studies are needed to define specific use cases and establish relevant thresholds for plasma p-tau217 as a biomarker for AD pathology, particularly for prescreening patients in clinical trials.
  • Generalizability: While promising, the findings are from a specific trial population, and further research across diverse cohorts would be beneficial to confirm generalizability.

Summary updated

Abstract

Abstract Background TANGO was a Phase 2 clinical study designed to assess the safety and efficacy of gosuranemab, an anti‐tau monoclonal antibody, in participants with mild cognitive impairment due to Alzheimer’s disease (AD) or with mild AD dementia. Despite robust target engagement of unbound N‐terminal tau, the clinical efficacy endpoint was not met. In this exploratory analysis of TANGO participants, we examine plasma p‐tau217 levels to assess the feasibility of using this biomarker to identify patients with AD pathology and predict disease progression. Methods Plasma was collected from 554 randomized TANGO participants at baseline and up to Week 78. Plasma p‐tau217 was measured using the ALZpath Quanterix Simoa assay. Plasma p‐tau181 was measured using the Quanterix Simoa p‐tau181 V2 Advantage assay. Tau PET was measured in a sub‐study of 357 participants at baseline and Weeks 52 and 78 using 18 F‐MK‐6240. Amyloid PET was measured at screening using 18 F‐florbetapir in n = 322 participants Clinical decline was measured using the CDR‐SB, MMSE, ADAS‐Cog13 and ADCS‐ADL cognitive assessment scales. Statistical analysis was performed using Spearman correlation coefficient. Results Plasma p‐tau217 and plasma p‐tau181 were correlated at baseline (Spearman = 0.7617, p‐value &lt;0.0001). Baseline plasma p‐tau217 levels were correlated with both baseline amyloid PET using SUVR in a composite region of interest (Spearman = 0.4294, p‐value &lt;0.0001) and baseline Tau PET using SUVR in composite regions of interest corresponding to Braak stages I‐II, III‐IV, and V‐VI (Spearman range = 0.4075‐0.6163, p = value &lt;0.0001). Participants with higher concentrations of plasma ptau217 at baseline showed a greater rate of clinical decline at Week 78. Conclusions The correlations of plasma p‐tau217 with amyloid and tau PET at baseline suggest a relationship with both underlying pathological hallmarks of AD. Similar to results from observational cohorts, correlation of baseline plasma p‐tau217 and clinical decline observed during the TANGO trial supports the utility of plasma p‐tau217 as a potential prognostic biomarker of disease. Data from additional studies are needed to define appropriate use cases and relevant thresholds for plasma p‐tau217 as a biomarker of disease pathology that can be used to prescreen patients in clinical trials.
BibTeX
@inproceedings{czerkowicz2024assessment,
  author = {Julie Czerkowicz and Rui Zhang and Jessica Collins and Carrie E. Rubel and John O’Gorman and Melanie Shulman and Danielle Graham},
  title = {{Assessment of Baseline Plasma p‐tau217 in TANGO, a Randomized, Placebo‐controlled Phase 2 Study of Gosuranemab in Patients with Early Alzheimer’s Disease}},
  booktitle = {Alzheimer},
  year = {2024},
  doi = {10.1002/alz.095703},
}
Figure